Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) shares dropped 4.5% on Monday . The stock traded as low as $34.61 and last traded at $34.77. Approximately 876,173 shares traded hands during mid-day trading, a decline of 12% from the average daily volume of 990,070 shares. The stock had previously closed at $36.42. Wall Street Analysts Forecast […]
Cytokinetics (NASDAQ:CYTK – Get Rating) had its price target cut by Cantor Fitzgerald from $61.00 to $59.00 in a report issued on Monday, The Fly reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Other analysts have also issued reports about the company. Oppenheimer dropped their target price on Cytokinetics from $55.00 […]
Cytokinetics (NASDAQ:CYTK – Get Rating) had its target price decreased by UBS Group from $67.00 to $61.00 in a research report report published on Monday, The Fly reports. UBS Group currently has a buy rating on the biopharmaceutical company’s stock. Other analysts have also issued reports about the stock. JPMorgan Chase & Co. lowered their […]
Cytokinetics (NASDAQ:CYTK – Get Rating) had its price objective decreased by Bank of America from $50.00 to $42.00 in a research report released on Sunday, The Fly reports. CYTK has been the topic of a number of other research reports. JPMorgan Chase & Co. dropped their price target on shares of Cytokinetics from $64.00 to […]
Cytokinetics (NASDAQ:CYTK – Get Rating) had its target price decreased by Cantor Fitzgerald from $61.00 to $59.00 in a report issued on Monday morning, The Fly reports. Cantor Fitzgerald currently has an overweight rating on the biopharmaceutical company’s stock. Other equities research analysts also recently issued reports about the company. JPMorgan Chase & Co. cut […]